Karthik Nath
Research Subjects
Research Interests
Karthik Nath has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
Georgina Hodges
Department of Haematology and Bone Marrow Transplantation The Townsville Hospital Townsville Queensland Australia
3 shared publicationsIan Irving
Icon Cancer Centre Wesley Brisbane Queensland Australia
3 shared publications- Maher K. Gandhi
Mater Research, University of Queensland and Translational Research Institute
3 shared publications Michael Scordo
Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York
3 shared publications- Miguel-Angel Perales
Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 shared publications Ana Alarcon Tomas
Division of Hematology and Hemotherapy, Hospital General Universitario Gregorio Marañón, Madrid, Spain
2 shared publications
Latest Publications
- Open Access
- 17 August 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (11) , 2096-2107
Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma
In classical Hodgkin lymphoma (cHL), responsiveness to immune‐checkpoint blockade (ICB) is associated with specific tumor microenvironment (TME) and peripheral blood features. The role of ICB in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is not established. To gain insights into its potential in NLPHL, we compared TME and peripheral blood signatures between HLs using an integrative multiomic analysis. A discovery/validation approach in 121 NLPHL and 114 cHL patients highlighted >2‐fold enrichment in programmed cell death‐1 (PD‐1) and T‐cell Ig and ITIM domain (TIGIT) gene expression for NLPHL versus cHL. Multiplex imaging showed marked increase in intra‐tumoral protein expression of PD‐1+ (and/or TIGIT+) CD4+ T‐cells and PD‐1+CD8+ T‐cells in NLPHL compared to cHL. This included T‐cells that rosetted with lymphocyte predominant (LP) and Hodgkin Reed–Sternberg (HRS) cells. In NLPHL, intra‐tumoral PD‐1+CD4+ T‐cells frequently expressed TCF‐1, a marker of heightened T‐cell response to ICB. The peripheral blood signatures between HLs were also distinct, with higher levels of PD‐1+TIGIT+ in TH1, TH2, and regulatory CD4+ T‐cells in NLPHL versus cHL. Circulating PD‐1+CD4+ had high levels of TCF‐1. Notably, in both lymphomas, highly expanded populations of clonal TIGIT+PD‐1+CD4+ and TIGIT+PD‐1+CD8+ T‐cells in the blood were also present in the TME, indicating that immune‐checkpoint expressing T‐cells circulated between intra‐tumoral and blood compartments. In in vitro assays, ICB was capable of reducing rosette formation around LP and HRS cells, suggesting that disruption of rosetting may be a mechanism of action of ICB in HL. Overall, results indicate that further evaluation of ICB is warranted in NLPHL.
- 17 August 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (11) , 2096-2107
Open AccessIntra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma
In classical Hodgkin lymphoma (cHL), responsiveness to immune‐checkpoint blockade (ICB) is associated with specific tumor microenvironment (TME) and peripheral blood features. The role of ICB in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is not established. To gain insights into its potential in NLPHL, we compared TME and peripheral blood signatures between HLs using an integrative multiomic analysis. A discovery/validation approach in 121 NLPHL and 114 cHL patients highlighted >2‐fold enrichment in programmed cell death‐1 (PD‐1) and T‐cell Ig and ITIM domain (TIGIT) gene expression for NLPHL versus cHL. Multiplex imaging showed marked increase in intra‐tumoral protein expression of PD‐1+ (and/or TIGIT+) CD4+ T‐cells and PD‐1+CD8+ T‐cells in NLPHL compared to cHL. This included T‐cells that rosetted with lymphocyte predominant (LP) and Hodgkin Reed–Sternberg (HRS) cells. In NLPHL, intra‐tumoral PD‐1+CD4+ T‐cells frequently expressed TCF‐1, a marker of heightened T‐cell response to ICB. The peripheral blood signatures between HLs were also distinct, with higher levels of PD‐1+TIGIT+ in TH1, TH2, and regulatory CD4+ T‐cells in NLPHL versus cHL. Circulating PD‐1+CD4+ had high levels of TCF‐1. Notably, in both lymphomas, highly expanded populations of clonal TIGIT+PD‐1+CD4+ and TIGIT+PD‐1+CD8+ T‐cells in the blood were also present in the TME, indicating that immune‐checkpoint expressing T‐cells circulated between intra‐tumoral and blood compartments. In in vitro assays, ICB was capable of reducing rosette formation around LP and HRS cells, suggesting that disruption of rosetting may be a mechanism of action of ICB in HL. Overall, results indicate that further evaluation of ICB is warranted in NLPHL.
- 4 November 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (6) , 1184-1195
CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review
The emergence of chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment of hematologic malignancies, including multiple myeloma (MM). Two BCMA‐directed CAR T‐cell products — idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) — have received US Food and Drug Administration (FDA) approval for patients with relapsed/refractory MM who underwent four or more prior lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti‐CD38 monoclonal antibody). Despite producing unprecedented response rates in an otherwise difficult to treat patient population, CAR T‐cell therapies are commonly associated with immune‐related adverse events (e.g., cytokine release syndrome and neurotoxicity), cytopenias, and infections. Moreover, many patients continue to exhibit relapse post‐treatment, with resistance mechanisms yet to be fully understood. Ongoing basic, translational, and clinical research efforts are poised to generate deeper insights into the optimal utilization of these therapies, improve their efficacy, minimize associated toxicity, and identify new target antigens in patients with MM.
- 4 November 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (6) , 1184-1195
CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review
The emergence of chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment of hematologic malignancies, including multiple myeloma (MM). Two BCMA‐directed CAR T‐cell products — idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) — have received US Food and Drug Administration (FDA) approval for patients with relapsed/refractory MM who underwent four or more prior lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti‐CD38 monoclonal antibody). Despite producing unprecedented response rates in an otherwise difficult to treat patient population, CAR T‐cell therapies are commonly associated with immune‐related adverse events (e.g., cytokine release syndrome and neurotoxicity), cytopenias, and infections. Moreover, many patients continue to exhibit relapse post‐treatment, with resistance mechanisms yet to be fully understood. Ongoing basic, translational, and clinical research efforts are poised to generate deeper insights into the optimal utilization of these therapies, improve their efficacy, minimize associated toxicity, and identify new target antigens in patients with MM.
- Open Access
- 1 October 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (1) , 81-92
Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
- 1 October 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (1) , 81-92
Open AccessReduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
- 9 September 2023
- Published by Wiley in American Journal of Hematology
- Vol. 98 (12) , 1869-1876
Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for patients with acute leukemia. Despite this, studies have shown that only a minority of patients ultimately proceed to allo-HCT. The primary objective of this prospective, observational study was to identify the rate of allo-HCT in patients for whom it was recommended, and reasons why patients deemed appropriate and eligible for HCT did not subsequently undergo transplant. Between April 2016 and April 2021, adult patients with newly diagnosed or relapsed/refractory acute leukemia were enrolled at the time of induction/reinduction therapy. Initial transplantation workup and allo-HCT recommendations were made during the early phase of induction/reinduction. Of the 307 enrolled patients, allo-HCT was recommended to 85% (n = 259), of whom 66% (n = 170) underwent transplant. Donor sources comprised 54% human leukocyte antigen (HLA)-matched unrelated donors, 20% HLA-matched sibling donors and HLA-mismatched graft sources with 15% umbilical cord blood units, 8% HLA-mismatched unrelated donors, and 4% HLA-haploidentical donors. The most common reason for transplant disqualification in the 89 patients in whom it was initially recommended was persistent/relapsed disease (70%), followed by early patient death (10%). In this prospective study, we report a high allo-HCT rate, which may be due to early transplant referral and workup. The main allo-HCT barrier was disease control, followed by early patient death. With the increasing availability of HLA-mismatched graft sources, the lack of donor availability was not a transplant barrier. Further development of novel transplant strategies for patients not achieving remission and improvements in induction regimens could result in increased allo-HCT utilization.
- 9 September 2023
- Published by Wiley in American Journal of Hematology
- Vol. 98 (12) , 1869-1876
Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for patients with acute leukemia. Despite this, studies have shown that only a minority of patients ultimately proceed to allo-HCT. The primary objective of this prospective, observational study was to identify the rate of allo-HCT in patients for whom it was recommended, and reasons why patients deemed appropriate and eligible for HCT did not subsequently undergo transplant. Between April 2016 and April 2021, adult patients with newly diagnosed or relapsed/refractory acute leukemia were enrolled at the time of induction/reinduction therapy. Initial transplantation workup and allo-HCT recommendations were made during the early phase of induction/reinduction. Of the 307 enrolled patients, allo-HCT was recommended to 85% (n = 259), of whom 66% (n = 170) underwent transplant. Donor sources comprised 54% human leukocyte antigen (HLA)-matched unrelated donors, 20% HLA-matched sibling donors and HLA-mismatched graft sources with 15% umbilical cord blood units, 8% HLA-mismatched unrelated donors, and 4% HLA-haploidentical donors. The most common reason for transplant disqualification in the 89 patients in whom it was initially recommended was persistent/relapsed disease (70%), followed by early patient death (10%). In this prospective study, we report a high allo-HCT rate, which may be due to early transplant referral and workup. The main allo-HCT barrier was disease control, followed by early patient death. With the increasing availability of HLA-mismatched graft sources, the lack of donor availability was not a transplant barrier. Further development of novel transplant strategies for patients not achieving remission and improvements in induction regimens could result in increased allo-HCT utilization.
- 2 January 2023
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 22 (1) , 5-15
Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma
: CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a highly effective therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL) and three CD19 CAR T-cell products (a...
- 2 January 2023
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 22 (1) , 5-15
Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma
: CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a highly effective therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL) and three CD19 CAR T-cell products (a...
- 25 October 2022
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (14) , 3488-3492
A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
Despite the improved complete response (CR) rates in multiple myeloma with newer therapies, most patients still relapse [1]. In this regard, there has been development of more sensitive tools for r...
- 25 October 2022
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (14) , 3488-3492
A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
Despite the improved complete response (CR) rates in multiple myeloma with newer therapies, most patients still relapse [1]. In this regard, there has been development of more sensitive tools for r...
- 4 September 2022
- Published by Wiley in Internal Medicine Journal
- Vol. 53 (6) , 923-929
Activity and outcomes of autologous stem cell transplantation in the private sector in Australia
Background: Few Australasian autologous stem cell transplantation (ASCT) programmes perform ASCT in the private sector. Relatively little is known about ASCT outcomes in the private sector, which varies in care delivery models to the public system.Aims: To investigate transplantation activity and survival outcomes at Icon Cancer Centre's Brisbane‐based private clinical and laboratory ASCT programme over a 23‐year period.Methods: Retrospective, observational study of all adults who underwent ASCT at Icon between 1996 and 2018. Main outcome measures were transplant activity, overall survival (OS) and 100‐day and 1‐year transplant‐related mortality (TRM). Outcomes were benchmarked against the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR).Results: Between 1996 and 2018, 1676 ASCT were performed in 1454 patients. From 2010 to 2018, ASCT performed at Icon contributed 40% of all South East Queensland ASCT. In the past 5 years, 21% of Icon's patients were aged ≥70 years, compared with 5% across Australasia. For the entire cohort, 100‐day and 1‐year TRM was 1.1% and 1.7%, respectively, while for those aged ≥70 years, it was 2.0% and 3.1%. For ASCT performed between 2014 and 2018, 100‐day and 1‐year TRM was 0.8% and 1.4%, which was half the TRM rates reported by the ABMTRR. The 10‐year post‐transplant OS at Icon was higher than the ABMTRR data, across all disease subtypes.Conclusion: We report excellent OS and low TRM, demonstrating the critical role of the private sector in the administration of this highly complex therapy. The Icon ASCT programme is the largest ASCT contributor in Queensland. It is inclusive of patients aged ≥70 years, demonstrating low and acceptable TRM.
- 4 September 2022
- Published by Wiley in Internal Medicine Journal
- Vol. 53 (6) , 923-929
Activity and outcomes of autologous stem cell transplantation in the private sector in Australia
Background: Few Australasian autologous stem cell transplantation (ASCT) programmes perform ASCT in the private sector. Relatively little is known about ASCT outcomes in the private sector, which varies in care delivery models to the public system.Aims: To investigate transplantation activity and survival outcomes at Icon Cancer Centre's Brisbane‐based private clinical and laboratory ASCT programme over a 23‐year period.Methods: Retrospective, observational study of all adults who underwent ASCT at Icon between 1996 and 2018. Main outcome measures were transplant activity, overall survival (OS) and 100‐day and 1‐year transplant‐related mortality (TRM). Outcomes were benchmarked against the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR).Results: Between 1996 and 2018, 1676 ASCT were performed in 1454 patients. From 2010 to 2018, ASCT performed at Icon contributed 40% of all South East Queensland ASCT. In the past 5 years, 21% of Icon's patients were aged ≥70 years, compared with 5% across Australasia. For the entire cohort, 100‐day and 1‐year TRM was 1.1% and 1.7%, respectively, while for those aged ≥70 years, it was 2.0% and 3.1%. For ASCT performed between 2014 and 2018, 100‐day and 1‐year TRM was 0.8% and 1.4%, which was half the TRM rates reported by the ABMTRR. The 10‐year post‐transplant OS at Icon was higher than the ABMTRR data, across all disease subtypes.Conclusion: We report excellent OS and low TRM, demonstrating the critical role of the private sector in the administration of this highly complex therapy. The Icon ASCT programme is the largest ASCT contributor in Queensland. It is inclusive of patients aged ≥70 years, demonstrating low and acceptable TRM.
- Open Access
- 6 August 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (11) , 751.e1-751.e7
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma
- 6 August 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (11) , 751.e1-751.e7
Open AccessVitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma
- 18 November 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (11) , 1981-1982
Hepatitis B in haematology patients receiving intravenous immunoglobulin: highlighting a core issue
- 18 November 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (11) , 1981-1982
Hepatitis B in haematology patients receiving intravenous immunoglobulin: highlighting a core issue